On Tuesday, Viking Holdings (NYSE:VIK) received continued support from BTIG with a reiterated Buy rating and a steady price target of $125. The endorsement follows the company's recent presentation of preclinical data at the American Diabetes Association meeting held on June 21-24 in Orlando.
Viking shared promising results from their studies on dual amylin and calcitonin receptor agonists (DACRAs), showcasing weight loss effects in rodent models.
The company's DACRAs, particularly VK3012, demonstrated up to an 8% mean reduction in body weight in lean rats over a 72-hour period and up to a 10% reduction in Diet-Induced Obese (DIO) rats over 24 days. These outcomes were favorably compared to a positive control from Novo Nordisk (NYSE:NVO), with VK3012 showing superior performance in reducing food intake, weight, and blood glucose levels in DIO mice.
The data presented by Viking is seen as a significant step forward in the company's development of treatments for obesity. The research indicates that Viking's DACRA could potentially have a best-in-class profile within their Obesity portfolio. The company has announced plans to continue advancing its internal DACRA development program.
BTIG's positive outlook is based on Viking's progress in creating compelling agents for the treatment of obesity, NASH, and rare diseases. The firm's confidence in Viking's potential is reflected in the reaffirmed Buy rating and the $125 price target for the company's shares.
In other recent news, Viking Holdings reported gross and net revenue of $718 million and $495 million, respectively, surpassing both Stifel's and consensus estimates. The company's operating losses were reported at $70 million, significantly better than anticipated.
Analysts from Stifel maintained a Buy rating and $37.00 price target for the company, recognizing its strong financial performance. Wells Fargo initiated coverage with an Overweight rating, highlighting Viking's unique luxury strategy. Similarly, JPMorgan initiated coverage with an Overweight rating, projecting a 15% compound annual growth rate in revenue through 2026 for Viking.
Redburn-Atlantic launched coverage with a Neutral rating, acknowledging the company's significant growth and potential. UBS started coverage with a Buy rating, underscoring Viking's robust financial health and high returns on invested capital.
These are recent developments that provide insights into Viking Holdings' financial health and market position.
InvestingPro Insights
As Viking Holdings (NYSE:VIK) continues to make strides in the medical field with their innovative DACRAs, investors are taking note of the company's financial health and market performance. According to the latest data from InvestingPro, Viking Holdings is a prominent player in the Hotels, Restaurants & Leisure industry, despite not being profitable over the last twelve months. However, analysts predict the company will turn a profit this year, which could be a pivotal moment for Viking’s financial trajectory. With a market capitalization of $13.69 billion and a strong return over the last three months, Viking Holdings is trading near its 52-week high. The company's revenue growth of 14.18% in the first quarter of 2024 indicates a robust upward trend.
InvestingPro Tips suggest that while Viking operates with a moderate level of debt, its short-term obligations currently exceed its liquid assets, which could be a point of consideration for potential investors. Additionally, Viking does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income. For a more in-depth analysis, including additional tips, investors can visit InvestingPro's comprehensive platform, and don’t forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.